Chemical structure of valaciclovir
Find information on thousands of medical conditions and prescription drugs.

Valtrex

Valaciclovir (INN) or valacyclovir (USAN) is an antiviral drug used in the management of herpes simplex. It is a prodrug, being converted in vivo to aciclovir. It is currently marketed by GlaxoSmithKline under the trade name Valtrex.


Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
Hydrocodone
Vagifem
Valaciclovir
Valcyte
Valganciclovir
Valine
Valium
Valnoctamide
Valproate semisodium
Valproic acid
Valpromide
Valrelease
Valsartan
Valstar
Valtrex
Vancenase
Vanceril
Vancomycin
Vaniqa
Vanticon
Vecuronium bromide
Velcade
Velivet
Venlafaxine
Ventolin
Vepesid
Verapamil
Verelan
Vermox
Versed
Vfend
Viadur
Viagra
Vicoprofen
Vidarabine
Vidaza
Videx
Vigabatrin
Viloxazine
Vinblastine
Vincristine
Vinorelbine
Viomycin
Vioxx
Viracept
Viread
Visine
Vistide
Visudyne
Vitaped
Vitrase
Vivelle
Volmax
Voltaren
Voriconazole
Vosol
W
X
Y
Z

Read more at Wikipedia.org


[List your site here Free!]


Valtrex approved by FDA for reducing spread of genital herpes - valacyclovir HCl - Pipeline Previews
From Journal of Drugs in Dermatology, 12/1/03

Valtrex[TM] (valacyclovir hydrochloride) has recently received expanded labeling indication by the U.S. Food and Drug Administration (FDA). Once daily 500 mg Valtrex Capleta have been approved for suppressive therapy in healthy adults with genital herpes in order to reduce the risk of transmission. It is estimated that 1 in 5 Americans are infected with the virus that causes genital herpes. However, as many as nine out of ten of those are unaware they have genital herpes, and clinical studies show that the majority of people with genital herpes contracted the disease from a partner who was otherwise asympmmatic.

In an eight month study of 1,484 healthy, heterosexual, monogamous couples, once daily suppressive therapy with Valtrex 500 mg caplets reduced the risk of transmission of symptomatic genital herpes by 75 percent versus placebo (0.5 percent on Valtrex vs. 2.2 percent on placebo). The primary, endpoint of the study was signs or symptoms of genital herpes to the uninfected partner. Reduced transmission was further con firmed with laboratory testing, and suppression therapy reduced rate of serologic conversion by 48 percent versus placebo (1.9 percent on Valtrex vs. 3.6 percent on placebo).

Valtrex is currently indicated for the treatment or suppression of genital herpes in healthy individuals and for the suppression of recurrent genital herpes in HIV-infected adults with CD4+ counts [greater than or equal to] 100 cells/uL. The most commonly reported side effects include headaches and upper respiratory symptoms. The effect of Valtrex on transmission of genital herpes has not been established in immunocompromised individuals or same-sex couples. The effect of Valtrex on reducing transmission beyond eight months has not been established.

Valtrex (valacyclovir hydrochloride) is manufactured and developed by GlaxoSmithKline.

COPYRIGHT 2003 Journal of Drugs in Dermatology
COPYRIGHT 2004 Gale Group

Return to Valtrex
Home Contact Resources Exchange Links ebay